Regulation of carcinogenesis and mediation through Wnt/β-catenin signaling by 3,3′-diindolylmethane in an enzalutamide-resistant prostate cancer cell line

Abstract Enzalutamide (ENZ) is an important drug used to treat castration-resistant prostate cancer (CRPC), which inhibits androgen receptor (AR) signaling. Previous study showed that 3,3′-diindolylmethane (DIM) is an AR antagonist that also inhibits Wnt signaling and epithelial-mesenchymal transiti...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chih-Wei Tsao, Jia-Sin Li, Ya-Wen Lin, Sheng-Tang Wu, Tai-Lung Cha, Chin-Yu Liu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a801bc9d8c684eddbab310572a29d920
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a801bc9d8c684eddbab310572a29d920
record_format	dspace
spelling	oai:doaj.org-article:a801bc9d8c684eddbab310572a29d9202021-12-02T14:01:20ZRegulation of carcinogenesis and mediation through Wnt/β-catenin signaling by 3,3′-diindolylmethane in an enzalutamide-resistant prostate cancer cell line10.1038/s41598-020-80519-32045-2322https://doaj.org/article/a801bc9d8c684eddbab310572a29d9202021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-80519-3https://doaj.org/toc/2045-2322Abstract Enzalutamide (ENZ) is an important drug used to treat castration-resistant prostate cancer (CRPC), which inhibits androgen receptor (AR) signaling. Previous study showed that 3,3′-diindolylmethane (DIM) is an AR antagonist that also inhibits Wnt signaling and epithelial-mesenchymal transition (EMT). To investigate whether combined treatment with ENZ and DIM can overcome ENZ resistance by regulating Wnt signaling to inhibit AR signaling and EMT in ENZ-resistant prostate cancer cells, 22Rv1 cells were cultured in normal medium and treated with ENZ, DIM, and DIM with ENZ. Exposure of ENZ-resistant cells to both DIM and ENZ significantly inhibited cell proliferation without cytotoxicity and invasion in comparison with the control. DIM significantly increased the E-cadherin expression and inhibited the expressions of Vimentin and Fibronectin, subsequently inhibiting EMT. Co-treatment with ENZ and DIM significantly increased the expressions of GSK3β and APC and decreased the β-catenin protein expression, causing inhibition of Wnt signaling and AR expression, it also significantly decreased the AR-v7 expression and down-regulated AR signaling. Via suppression of Wnt and AR signaling, co-treatment increased the E-cadherin and decreased the Vimentin and Fibronectin RNA and protein expressions, then inhibited EMT. Co-treatment with DIM and ENZ regulated Wnt signaling to reduce not only the AR expression, but also the AR-v7 expression, indicating suppression of EMT that inhibits cancer cell proliferation, invasion and migration to ameliorate ENZ resistance.Chih-Wei TsaoJia-Sin LiYa-Wen LinSheng-Tang WuTai-Lung ChaChin-Yu LiuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-18 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Chih-Wei Tsao Jia-Sin Li Ya-Wen Lin Sheng-Tang Wu Tai-Lung Cha Chin-Yu Liu Regulation of carcinogenesis and mediation through Wnt/β-catenin signaling by 3,3′-diindolylmethane in an enzalutamide-resistant prostate cancer cell line
description	Abstract Enzalutamide (ENZ) is an important drug used to treat castration-resistant prostate cancer (CRPC), which inhibits androgen receptor (AR) signaling. Previous study showed that 3,3′-diindolylmethane (DIM) is an AR antagonist that also inhibits Wnt signaling and epithelial-mesenchymal transition (EMT). To investigate whether combined treatment with ENZ and DIM can overcome ENZ resistance by regulating Wnt signaling to inhibit AR signaling and EMT in ENZ-resistant prostate cancer cells, 22Rv1 cells were cultured in normal medium and treated with ENZ, DIM, and DIM with ENZ. Exposure of ENZ-resistant cells to both DIM and ENZ significantly inhibited cell proliferation without cytotoxicity and invasion in comparison with the control. DIM significantly increased the E-cadherin expression and inhibited the expressions of Vimentin and Fibronectin, subsequently inhibiting EMT. Co-treatment with ENZ and DIM significantly increased the expressions of GSK3β and APC and decreased the β-catenin protein expression, causing inhibition of Wnt signaling and AR expression, it also significantly decreased the AR-v7 expression and down-regulated AR signaling. Via suppression of Wnt and AR signaling, co-treatment increased the E-cadherin and decreased the Vimentin and Fibronectin RNA and protein expressions, then inhibited EMT. Co-treatment with DIM and ENZ regulated Wnt signaling to reduce not only the AR expression, but also the AR-v7 expression, indicating suppression of EMT that inhibits cancer cell proliferation, invasion and migration to ameliorate ENZ resistance.
format	article
author	Chih-Wei Tsao Jia-Sin Li Ya-Wen Lin Sheng-Tang Wu Tai-Lung Cha Chin-Yu Liu
author_facet	Chih-Wei Tsao Jia-Sin Li Ya-Wen Lin Sheng-Tang Wu Tai-Lung Cha Chin-Yu Liu
author_sort	Chih-Wei Tsao
title	Regulation of carcinogenesis and mediation through Wnt/β-catenin signaling by 3,3′-diindolylmethane in an enzalutamide-resistant prostate cancer cell line
title_short	Regulation of carcinogenesis and mediation through Wnt/β-catenin signaling by 3,3′-diindolylmethane in an enzalutamide-resistant prostate cancer cell line
title_full	Regulation of carcinogenesis and mediation through Wnt/β-catenin signaling by 3,3′-diindolylmethane in an enzalutamide-resistant prostate cancer cell line
title_fullStr	Regulation of carcinogenesis and mediation through Wnt/β-catenin signaling by 3,3′-diindolylmethane in an enzalutamide-resistant prostate cancer cell line
title_full_unstemmed	Regulation of carcinogenesis and mediation through Wnt/β-catenin signaling by 3,3′-diindolylmethane in an enzalutamide-resistant prostate cancer cell line
title_sort	regulation of carcinogenesis and mediation through wnt/β-catenin signaling by 3,3′-diindolylmethane in an enzalutamide-resistant prostate cancer cell line
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/a801bc9d8c684eddbab310572a29d920
work_keys_str_mv	AT chihweitsao regulationofcarcinogenesisandmediationthroughwntbcateninsignalingby33diindolylmethaneinanenzalutamideresistantprostatecancercellline AT jiasinli regulationofcarcinogenesisandmediationthroughwntbcateninsignalingby33diindolylmethaneinanenzalutamideresistantprostatecancercellline AT yawenlin regulationofcarcinogenesisandmediationthroughwntbcateninsignalingby33diindolylmethaneinanenzalutamideresistantprostatecancercellline AT shengtangwu regulationofcarcinogenesisandmediationthroughwntbcateninsignalingby33diindolylmethaneinanenzalutamideresistantprostatecancercellline AT tailungcha regulationofcarcinogenesisandmediationthroughwntbcateninsignalingby33diindolylmethaneinanenzalutamideresistantprostatecancercellline AT chinyuliu regulationofcarcinogenesisandmediationthroughwntbcateninsignalingby33diindolylmethaneinanenzalutamideresistantprostatecancercellline
_version_	1718392219522564096

Regulation of carcinogenesis and mediation through Wnt/β-catenin signaling by 3,3′-diindolylmethane in an enzalutamide-resistant prostate cancer cell line

Ejemplares similares